Pregabalin Capsule
Product Images NDC 70518-2763

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-2763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description of a medication called Pregabalin. The medication is a 200mg capsule manufactured by Novadoz Pharmaceuticals LLC. It comes in a quantity of 90, and the National Drug Code (NDC) is 70518-2763-00. The expiration date and Lot number are not available. The medication should be stored between 20-26°C (63-77°F) with permitted excursions to 15-30°C (59-86°F). It is advised to keep medicine away from children. Additional information can be found in the package insert. This is a prescription-only medication that is repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Equation (Pregabain Gault Equation)

This text provides a formula to calculate CLCr, which stands for creatinine clearance, a measure of kidney function. The formula includes age, weight, and serum creatinine levels, with a different coefficient for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

The text describes the percent of patients who improved with various doses of Pregabalin and placebo. It also includes a graphical representation of the percent improvement in pain from baseline.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This is a chart that displays the percentage of patients who improved while taking Pregabalin 100mg three times a day compared to a placebo. The chart represents the percentage of improvement in pain levels from baseline, with increments of 10%, going from 0 to 100%.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This is a table that represents the percentage of patients improved using different doses of pregabalin and a placebo. The table also includes the percentage improvement in pain of the patients from the baseline.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This appears to be a chart displaying the percentage of patients whose pain levels improved based on the dosage of Pregabalin taken. The X-axis shows the percentage improvement in pain from the baseline, while the Y-axis shows the percentage of patients who saw that level of improvement. There are three lines representing different dosages of Pregabalin as well as a placebo.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This appears to be a chart or graph that shows the percentage of patients who experienced improvement in pain after taking either pregabalin 100mg three times a day, pregabalin 50mg three times a day, or a placebo. The chart also includes the percentage of improvement in pain from baseline.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This appears to be a table of data regarding a study on a medication or treatment. The top row shows responder rates in percentages, with different dosages listed in the left column. The dosages include 50mg/day, 150mg/day, 300mg/day, and 600mg/day. In some cases, statistically significant improvements were observed compared to a placebo. There are also references to different studies labeled E1 and E3. However, there is not enough context to determine the specific treatment or condition being studied.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This is a graph that shows the percent of patient improvement and the percent of improvement in pain from baseline. The graph includes four different doses of Pregabalin and a placebo. The x-axis displays the percent of improvement in pain from baseline ranging from 20 to 100 while the y-axis displays the percent of patient improvement ranging from 0 to 100.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This is a chart that shows the percent of subjects improved from baseline to week 12. The chart compares the results between two groups, Pregabalin and Placebo. The X-axis shows percentage points from 0 to 100, and the Y-axis shows the percentage of subjects improved. It indicates that the Pregabalin group had higher percentages of improvement compared to the Placebo group.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

The text provided is a table showing the percentage of subjects who improved after taking Pregabalin or Placebo for 16 weeks. The table has different percentages ranging from 0 to 100 in increments of 10, and the number of subjects who improved at each percentage is indicated. There is no additional context to provide a more detailed description.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.